Search - tctmd.com

Displaying 1 - 10 of 10

Sort: Relevancy | Date

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Conference News ESC 2024

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

Yael L. Maxwell

September 10, 2024

News Daily News

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

Yael L. Maxwell

March 21, 2024

News Conference News ESC 2022

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

Todd Neale

August 29, 2022

News Daily News

Site Investigators Missed Clinical Events in GLOBAL LEADERS

Michael O'Riordan

February 12, 2021

Presentation TCT 2019

Insights From GLOBAL LEADERS and GLASSY

Presenter: Pascal Vranckx

September 26, 2019

Presentation CIT 2019

Global Leaders and Glassy

Presenter: Patrick W. Serruys

March 28, 2019

News Conference News ACC 2019

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Yael L. Maxwell

March 27, 2019

Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Presentation ACC 2019

Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

Presenter: Marco Valgimigli

March 18, 2019

Video

» Interview

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

March 18, 2019

Advertisement

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

More Support for Ticagrelor Monotherapy After PCI, Especially in ACS

When Moving From DAPT to Monotherapy After PCI, the P2Y12 Inhibitor Matters

P2Y12 Inhibitors Top Aspirin for Long-term Secondary Prevention: PANTHER

Site Investigators Missed Clinical Events in GLOBAL LEADERS

Insights From GLOBAL LEADERS and GLASSY

Global Leaders and Glassy

Ticagrelor Monotherapy Noninferior to DAPT After PCI in Adjudicated-Events Analysis: GLASSY

Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)

ACC 2019: GLASSY: Impact of Ticagrelor Monotherapy Beyond One Month Versus Conventional Therapy On Adjudicated Ischemic And Bleeding Endpoints Following Drug Eluting Sent Implantation. Primary Results of the GLOBAL LEADERS Adjudication Sub-StudY

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content